254 related articles for article (PubMed ID: 33502794)
1. Sodium-glucose co-transporter 2 inhibitors-the first successful treatment for heart failure with preserved ejection fraction?
Petrie MC; Lee MMY; Docherty KF
Eur J Heart Fail; 2021 Aug; 23(8):1256-1259. PubMed ID: 33502794
[No Abstract] [Full Text] [Related]
2. Sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism.
Anker SD; Khan MS; Shahid I; Filippatos G; Coats AJS; Butler J
Eur J Heart Fail; 2021 Aug; 23(8):1250-1255. PubMed ID: 34173305
[No Abstract] [Full Text] [Related]
3. Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article 'Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial'.
Kokhan E; Kiyakbaev G; Medovchshikov V
Eur J Heart Fail; 2022 Jul; 24(7):1323-1324. PubMed ID: 35238461
[No Abstract] [Full Text] [Related]
4. Pharmacology Focus: Clinical Evidence for the Use of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction.
Berendse J; Newenhouse L
S D Med; 2022 Jul; 75(7):328-329. PubMed ID: 36542574
[No Abstract] [Full Text] [Related]
5. A mechanistic rationale for the investigation of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction. Letter regarding the article 'Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial'.
Pabel S; Hamdani N; Sossalla S
Eur J Heart Fail; 2021 May; 23(5):841. PubMed ID: 33377246
[No Abstract] [Full Text] [Related]
6. Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice.
Butler J; Zannad F; Filippatos G; Anker SD; Packer M
Eur Heart J; 2020 Sep; 41(36):3398-3401. PubMed ID: 32935133
[No Abstract] [Full Text] [Related]
7. Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
Tsampasian V; Elghazaly H; Chattopadhyay R; Ali O; Corballis N; Chousou PA; Clark A; Garg P; Vassiliou VS
Eur J Prev Cardiol; 2022 May; 29(6):e227-e229. PubMed ID: 34850881
[No Abstract] [Full Text] [Related]
8. Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists.
Volpe M; Gallo G
Cardiovasc Res; 2021 Jul; 117(9):1992-1994. PubMed ID: 33231613
[No Abstract] [Full Text] [Related]
9. Sodium-glucose co-transporter-2 inhibitors and sacubitril/valsartan combination in patients with heart failure with reduced ejection fraction; does it deserve our attention?
Patoulias D; Papadopoulos C; Doumas M
Am Heart J; 2021 Jun; 236():104-105. PubMed ID: 33902820
[No Abstract] [Full Text] [Related]
10. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology.
Seferović PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Çavuşoğlu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferović J; Jhund PS; Dattilo G; Čelutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; de Boer RA; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainščak M; Jankowska E; Mueller C; Cosentino F; Lund L; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC
Eur J Heart Fail; 2020 Sep; 22(9):1495-1503. PubMed ID: 32618086
[TBL] [Abstract][Full Text] [Related]
11. Another brick in the wall of cardioprotection? A meta-analysis addressing the effect of sodium-glucose co-transporter 2 inhibitors on left ventricular mass assessed by cardiovascular magnetic resonance in patients with heart failure with reduced ejection fraction.
Patoulias D; Boulmpou A; Doumas M; Papadopoulos CE
J Cardiovasc Med (Hagerstown); 2022 Aug; 23(8):570-572. PubMed ID: 35905005
[No Abstract] [Full Text] [Related]
12. Meta-Analysis Assessing the Impact of Major Co-Morbidities, Gender, and Race on Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors Among Patients With Heart Failure With Preserved or Reduced Ejection Fraction.
Patoulias D; Papadopoulos C; Imprialos K; Stavropoulos K; Doumas M
Am J Cardiol; 2022 Jan; 162():201-205. PubMed ID: 34688474
[No Abstract] [Full Text] [Related]
13. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
Anker SD; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Zannad F; Packer M;
Eur J Heart Fail; 2019 Oct; 21(10):1279-1287. PubMed ID: 31523904
[TBL] [Abstract][Full Text] [Related]
14. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
Butler J; Handelsman Y; Bakris G; Verma S
Eur J Heart Fail; 2020 Apr; 22(4):604-617. PubMed ID: 31926059
[TBL] [Abstract][Full Text] [Related]
15. Updated Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Surrogate End points in Patients With Heart Failure With Reduced Ejection Fraction.
Patoulias D; Papadopoulos C; Kalogirou MS; Katsimardou A; Toumpourleka M; Doumas M
Am J Cardiol; 2020 Dec; 137():130-132. PubMed ID: 33049238
[No Abstract] [Full Text] [Related]
16. [Serendipity of sodium-glucose co-transporter 2 inhibitors: a new paradigm in the management of heart failure with reduced ejection fraction].
Rosano G; Iacoviello M; Filardi PP
G Ital Cardiol (Rome); 2021 Apr; 22(4):277-283. PubMed ID: 33783447
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction.
Liang B; Liang Y; Gu N
BMC Cardiovasc Disord; 2022 Jun; 22(1):261. PubMed ID: 35689186
[TBL] [Abstract][Full Text] [Related]
18. Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?
Singh AK; Singh R; Misra A
J Diabetes; 2021 Jul; 13(7):596-600. PubMed ID: 33792199
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 Inhibitors Should Be Considered for All Patients With Heart Failure.
Ahmad T; Desai NR; Velazquez EJ
J Am Coll Cardiol; 2022 Oct; 80(14):1311-1313. PubMed ID: 36041913
[No Abstract] [Full Text] [Related]
20. Sodium-glucose co-transporter 2 inhibitors and mineralocorticoid receptor antagonists synergism in heart failure: it takes two to tango.
Bauersachs J; Soltani S
Eur Heart J; 2023 Oct; 44(37):3697-3699. PubMed ID: 37611060
[No Abstract] [Full Text] [Related]
[Next] [New Search]
